Exemplary embodiments relate to a novel anticancer composition including a compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient: ##STR00001##

Exemplary embodiments relate to a novel anticancer composition including a compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient: ##STR00001##

The present disclosure features compounds (e.g., oxaziridine-based compounds), as well as related compositions and methods of use thereof, e.g., for selectively labeling a methionine residue in a target peptide or protein.

The present disclosure features compounds (e.g., oxaziridine-based compounds), as well as related compositions and methods of use thereof, e.g., for selectively labeling a methionine residue in a target peptide or protein.

The invention provides for methods for the synthesis of various compounds through reaction of carboxamide, or carboxamide derivatives, with various substituted or unsubstituted haloalkanols in a one-step, single vessel, reaction mechanism. Preferably, but not exclusively, the reaction proceeds in the absence of any solvents, catalyst, base, or any further reagents.

The invention provides for methods for the synthesis of various compounds through reaction of carboxamide, or carboxamide derivatives, with various substituted or unsubstituted haloalkanols in a one-step, single vessel, reaction mechanism. Preferably, but not exclusively, the reaction proceeds in the absence of any solvents, catalyst, base, or any further reagents.

This disclosure relates to GLP-1 agonists of Formula I: ##STR00001##
including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

This disclosure relates to GLP-1 agonists of Formula I: ##STR00001##
including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

This disclosure relates to GLP-1 agonists of Formula I.

##STR00001##

including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

This disclosure relates to GLP-1 agonists of Formula I.

##STR00001##

including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.